Mike was a fundamental part of the formation and success of our companies. He was Executive Chairman at VaxEquity, and co-founder and CEO of MEVOX.
Over his long and distinguished career, working in the UK, France, and the USA, he made a significant impact on global vaccine R&D, clinical development, vaccine introduction and vaccination policy for diseases including HPV, polio, and influenza. He also thought beyond vaccines, exploring how novel technologies and platforms such as mRNA could be used therapeutically. His thinking and work had a significant impact on global public health.
We are privileged to have worked alongside such an empathic, enthusiastic, and exceptional person. We will continue Mike’s inspiring work to improve human health all around the world.
